Items where authors include "Howard, DR"

Article

Hillmen, P, Pitchford, A, Bloor, A et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Howard, DR, Hockaday, A, Brown, JM orcid.org/0000-0002-2719-7064 et al. (6 more authors) (2021) A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials, 22 (1). 38. ISSN 1745-6215

Alharthi, A, Beck, D, Howard, DR orcid.org/0000-0003-3333-9783 et al. (4 more authors) (2018) An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. BMC Research Notes, 11 (1). 280. ISSN 1756-0500

Howard, DR orcid.org/0000-0003-3333-9783, Brown, JM orcid.org/0000-0002-2719-7064, Todd, S et al. (1 more author) (2018) Recommendations on multiple testing adjustment in multi-arm trials with a shared control group. Statistical Methods in Medical Research, 27 (5). pp. 1513-1530. ISSN 0962-2802

Munir, T, Howard, DR orcid.org/0000-0003-3333-9783, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia, 31 (10). pp. 2085-2093. ISSN 0887-6924

Collett, L, Howard, DR orcid.org/0000-0003-3333-9783, Munir, T et al. (11 more authors) (2017) Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18. 387. ISSN 1745-6215

Oughton, JB orcid.org/0000-0002-2047-804X, Collett, L, Howard, DR orcid.org/0000-0003-3333-9783 et al. (8 more authors) (2017) GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 18. 353. ISSN 1745-6215

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL. Leukemia, 31. pp. 2416-2425. ISSN 0887-6924

Varghese, A, Howard, DR orcid.org/0000-0003-3333-9783, Pocock, C et al. (9 more authors) (2017) Eradication of minimal residual disease improves overall and progression free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: A Phase II trial assessing alemtuzumab consolidation. British Journal of Haematology, 176 (4). pp. 573-582. ISSN 0007-1048

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, Hockaday, AM et al. (7 more authors) (2016) Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17. 456. ISSN 1745-6215

Gregory, WM, Twelves, CJ, Bell, R et al. (4 more authors) (2016) Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Research and Treatment, 155 (2). pp. 303-311. ISSN 0167-6806

Monograph

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (9 more authors) (2017) Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Report. National Institute for Health Research , Health Technology Assessment. ISSN 1366-5278

Conference or Workshop Item

Howard, DR orcid.org/0000-0003-3333-9783, Brown, JM, Todd, S et al. (1 more author) (2016) Recommendations on multiple-testing adjustment in multi-arm trials with correlated hypotheses. In: International Society for Clinical Biostatistics (ISCB), 22 Aug 2016. (Unpublished)